{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:03:54Z","timestamp":1777485834178,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","plasticsurgery.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Plastic Surgery"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.cps.2021.06.001","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T09:29:45Z","timestamp":1629278985000},"page":"651-658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma"],"prefix":"10.1016","volume":"48","author":[{"given":"William J.","family":"Bruce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie L.","family":"Koljonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz U.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Neumeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cps.2021.06.001_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919866959","article-title":"Neoadjuvant therapy of locally\/regionally advanced melanoma","volume":"11","author":"Khunger","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.cps.2021.06.001_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/BF02305762","article-title":"Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial","volume":"3","author":"Karakousis","year":"1996","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.cps.2021.06.001_bib3","first-page":"101","article-title":"Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1\u20134 mm melanomas","volume":"8","author":"Balch","year":"2001","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"10.1016\/j.cps.2021.06.001_bib4","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2005.05.2498","article-title":"Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses","volume":"24","author":"Moschos","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.cps.2021.06.001_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-019-0858-3","article-title":"The evolution of adjuvant therapy for melanoma","volume":"21","author":"Cohen","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"10.1016\/j.cps.2021.06.001_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.cps.2021.06.001_bib7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/jso.25298","article-title":"Updates in adjuvant systemic therapy for melanoma","volume":"119","author":"Kwak","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.cps.2021.06.001_bib8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (\u03b1\/\u03b2) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"19","key":"10.1016\/j.cps.2021.06.001_bib9","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1200\/JCO.2005.04.5344","article-title":"Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma","volume":"24","author":"Lewis","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"9492","key":"10.1016\/j.cps.2021.06.001_bib10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomised controlled trial","volume":"366","author":"Eggermont","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cps.2021.06.001_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis","volume":"102","author":"Mocellin","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.cps.2021.06.001_bib12","first-page":"982","article-title":"Practical guidelines for the management of interferon-\u03b1-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion","volume":"112","author":"Hauschild","year":"2008","journal-title":"Cancer Interdiscip Int J Am Cancer Soc"},{"key":"10.1016\/j.cps.2021.06.001_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","article-title":"Adjuvant interferon-\u03b1 for the treatment of high-risk melanoma: an individual patient data meta-analysis","volume":"82","author":"Ives","year":"2017","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.cps.2021.06.001_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.cps.2021.06.001_bib15","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.cps.2021.06.001_bib16","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cps.2021.06.001_bib17","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma","volume":"10","author":"Berman","year":"2010","journal-title":"Cancer Immun Archive"},{"key":"10.1016\/j.cps.2021.06.001_bib18","article-title":"Neoadjuvant ipilimumab in locally\/regionally advanced melanoma: clinical outcome and biomarker analysis","author":"Tarhini","year":"2012","journal-title":"Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.cps.2021.06.001_bib19","doi-asserted-by":"crossref","first-page":"e87705","DOI":"10.1371\/journal.pone.0087705","article-title":"Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab","volume":"9","author":"Tarhini","year":"2014","journal-title":"PLoS One"},{"issue":"26","key":"10.1016\/j.cps.2021.06.001_bib20","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.cps.2021.06.001_bib21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cps.2021.06.001_bib22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cps.2021.06.001_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000478081","article-title":"Adverse reactions to biologics: melanoma (ipilimumab, nivolumab, pembrolizumab)","volume":"53","author":"Hwang","year":"2018","journal-title":"Curr Probl Dermatol"},{"issue":"2","key":"10.1016\/j.cps.2021.06.001_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.cps.2021.06.001_bib25","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.cps.2021.06.001_bib26","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.cps.2021.06.001_bib27","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.cps.2021.06.001_bib28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A\u00a0single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.cps.2021.06.001_bib29","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.cps.2021.06.001_bib30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-018-0048-5","article-title":"The new era of adjuvant therapies for melanoma","volume":"15","author":"Eggermont","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"10.1016\/j.cps.2021.06.001_bib31","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cps.2021.06.001_bib32","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"6411","key":"10.1016\/j.cps.2021.06.001_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.cps.2021.06.001_bib34","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9839","key":"10.1016\/j.cps.2021.06.001_bib35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.cps.2021.06.001_bib36","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cps.2021.06.001_bib37","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cps.2021.06.001_bib38","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","article-title":"Cutaneous toxicities of RAF inhibitors","volume":"14","author":"Anforth","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cps.2021.06.001_bib39","first-page":"2251","article-title":"Trametinib: a MEK inhibitor for management of metastatic melanoma","volume":"8","author":"Lugowska","year":"2015","journal-title":"OncoTargets Ther"},{"issue":"7","key":"10.1016\/j.cps.2021.06.001_bib40","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB\u2013C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cps.2021.06.001_bib41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management","volume":"119","author":"Gogas","year":"2019","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.cps.2021.06.001_bib42","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.cps.2021.06.001_bib43","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.cps.2021.06.001_bib44","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cps.2021.06.001_bib45","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/SLA.0000000000001419","article-title":"Long-term outcomes of helper peptide vaccination for metastatic melanoma","volume":"262","author":"Hu","year":"2015","journal-title":"Ann Surg"},{"issue":"25","key":"10.1016\/j.cps.2021.06.001_bib46","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cps.2021.06.001_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9508","article-title":"Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL)","author":"Andtbacka","year":"2018","journal-title":"Am Soc Clin Oncol"},{"key":"10.1016\/j.cps.2021.06.001_bib48","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9520","article-title":"Oneyear (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL)","author":"Dummer","year":"2019","journal-title":"Am Soc Clin Oncol"},{"issue":"10236","key":"10.1016\/j.cps.2021.06.001_bib49","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"}],"container-title":["Clinics in Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094129821000602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094129821000602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:26:02Z","timestamp":1758810362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094129821000602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0094129821000602"],"URL":"https:\/\/doi.org\/10.1016\/j.cps.2021.06.001","relation":{},"ISSN":["0094-1298"],"issn-type":[{"value":"0094-1298","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma","name":"articletitle","label":"Article Title"},{"value":"Clinics in Plastic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cps.2021.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}